quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 13, 2026

JPMorgan Chase & Co. Q4 Earnings Call Highlights

View original at finance.yahoo.com
JPMorgan Chase & Co. Q4 Earnings Call Highlights JPMorgan Chase & Co. logo Key Points JPMorgan reported Q4 net income of $13 billion and EPS of $4.63 on revenue of $46.8 billion (up 7% YoY) with ROTCE of 18%, and full‑year net income of $57.5 billion (EPS $20.18) excluding certain items…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 adjusted expense is expected to be about $105 billion

    80% confidence
  • Potential credit card APR caps would reduce access to credit broadly, especially for lower-FICO borrowers, and would be bad for JPMorgan

    80% confidence
  • The firm expects the 2026 card net charge-off rate to be approximately 3.4%, citing favorable delinquency trends and consumer resilience

    80% confidence
  • JPMorgan reported Q4 net income of $13 billion and earnings per share of $4.63, with return on tangible common equity of 18%

    80% confidence
  • The firm's stablecoin advocacy is focused on preventing the creation of a parallel banking system that functions like banking without prudential safeguards

    80% confidence
  • The Apple Card transaction is economically compelling and characterized as a win-win-win

    80% confidence
  • The elevated advanced RWA level is expected to be temporary and reduce to approximately $30 billion in the near term

    80% confidence
  • For 2026, NII ex-Markets is expected to be about $95 billion and total NII about $103 billion

    80% confidence
  • Revenue totaled $46.8 billion, up 7% year over year, attributed to higher markets revenue, higher asset management fees, and auto lease income

    80% confidence
  • The quarter included the previously announced reserve build of $2.2 billion in CCB related to the forward purchase commitment of the Apple Card portfolio

    80% confidence
  • The firm is making investments aligned with the greatest opportunities across businesses while the operating environment is becoming more competitive

    80% confidence
  • JPMorgan is not going to try to meet some expense target at the risk of being left behind competitively

    80% confidence
  • Real estate is a very small number as an expense driver

    80% confidence
  • JPMorgan reported about $160 billion of NBFI exposure as of Q4, with loss history since 2018 including only one charge-off related to apparent fraud

    80% confidence
  • An undifferentiated APR cap would be very dramatic in its impact

    80% confidence
  • Wholesale credit trends show nothing concerning, with downgrades slightly exceeding upgrades and small parameter updates increasing assumed loss given default

    80% confidence
  • The Apple Card commitment contributed about $23 billion of standardized RWA and about $110 billion on an advanced basis

    80% confidence
  • Consumers and small businesses remain resilient, with no current deterioration despite weak consumer sentiment

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com